| Sumario: | The article focuses on the urgent need to address the neglect of fungal and anaerobic bacterial pathogens in low- and middle-income countries (LMICs), particularly within antimicrobial resistance (AMR) strategies. It highlights that these pathogens are underdiagnosed due to limited diagnostic capacity, excluded from global surveillance systems like the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS), and receive minimal funding and policy attention compared to other infectious diseases. The authors propose expanding surveillance to include these pathogens, revising the WHO Essential Diagnostics List to incorporate relevant tests, investing in workforce training, and increasing research funding for diagnostics and therapeutics tailored to LMIC contexts. Addressing these gaps is presented as critical to improving patient outcomes, reducing inappropriate antimicrobial use, and strengthening health systems in LMICs.
|
|---|